Valeant Makes Its First Acquisition Move Of The Year, In Dermatology

Valeant Pharmaceuticals will continue its march into dermatology with the acquisition of PreCision Dermatology for $475 million in cash plus milestones. The deal represents a bolt-on opportunity for Valeant, which will leverage its existing infrastructure to sell PreCision’s products.